Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
87.40
+0.90 (1.04%)
At close: Feb 20, 2026, 4:00 PM EST
88.88
+1.48 (1.69%)
After-hours: Feb 20, 2026, 5:24 PM EST
Kymera Therapeutics Revenue
Kymera Therapeutics had revenue of $2.76M in the quarter ending September 30, 2025, a decrease of -26.12%. This brings the company's revenue in the last twelve months to $43.73M, down -50.05% year-over-year. In the year 2024, Kymera Therapeutics had annual revenue of $47.07M, down -40.11%.
Revenue (ttm)
$43.73M
Revenue Growth
-50.05%
P/S Ratio
159.87
Revenue / Employee
$194,378
Employees
225
Market Cap
6.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 47.07M | -31.52M | -40.11% |
| Dec 31, 2023 | 78.59M | 31.77M | 67.84% |
| Dec 31, 2022 | 46.83M | -26.01M | -35.71% |
| Dec 31, 2021 | 72.83M | 38.80M | 114.00% |
| Dec 31, 2020 | 34.03M | 31.10M | 1,059.99% |
| Dec 31, 2019 | 2.93M | - | - |
| Dec 31, 2018 | 2.93M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Halozyme Therapeutics | 1.40B |
| Mirum Pharmaceuticals | 471.79M |
| Krystal Biotech | 389.13M |
| Rhythm Pharmaceuticals | 174.33M |
| Cytokinetics | 87.21M |
| ImmunityBio | 82.56M |
KYMR News
- 5 weeks ago - Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs - GlobeNewsWire
- 2 months ago - Kymera Therapeutics Announces Closing of Upsized $602 Million Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Kymera Therapeutics Announces Proposed Public Offering - GlobeNewsWire
- 2 months ago - This Drugmaker's Stock Is Soaring Over 40% Monday - Investopedia
- 2 months ago - Kymera Therapeutics, Inc. (KYMR) Discusses KT-621 BroADen Phase 1b Results in Atopic Dermatitis Transcript - Seeking Alpha
- 2 months ago - Kymera's KT-621 Shines: Phase 1b Data Boosts Momentum - Seeking Alpha
- 2 months ago - Kymera Therapeutics Stock Soars 30%. Why Investors Are Excited About Its Anti-Inflammatory Drug. - Barrons